John Smallridge
Researcher at Reconnect Labs AG
Data updated
Papers
Trials
Research Footprint
John Smallridge appears in 6 tracked papers (2022–2026), most studied alongside Ayahuasca, Placebo and Psilocybin, across Neuroimaging & Brain Measures, Healthy Volunteers and Medicinal Chemistry & Drug Development.
Most-cited paper: Classic Psychedelic Drugs: Update on Biological Mechanisms (104 citations).
Frequent co-authors: Milan Scheidegger, Klemens Egger and Franz Vollenweider.
Background & Research
John W. Smallridge appears to be a researcher affiliated with Reconnect Labs AG in Winterthur, Switzerland. He is listed as a coauthor on studies spanning psychedelic drug mechanisms, DMT-harmine pharmacokinetics/pharmacodynamics, mindfulness-retreat research, and altered-states EEG work. Publicly available sources in this search did not clearly surface a more detailed academic bio or a unique faculty position.
Key Impact
He is a coauthor on several recent psychedelic pharmacology and consciousness studies involving DMT, harmine, psilocybin, and EEG/TMS-EEG methods.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations John Smallridge is associated with.
Reconnect Labs
Private BiotechReconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →